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’ INTRODUCTION
This paper describes a rotational SlipChip to quantify RNA
with large dynamic range by using multivolume digital RT-PCR
(MV digital RT-PCR). Quantitative detection of RNA provides
valuable information for study of gene expression1,2 and has the
potential to improve evaluation of diseases (including stroke,3
leukemia,4 and prostate cancer5), analysis of graft rejection in
transplantation,6 and vaccine development.7,8 Quantification of
viral RNA has also become increasingly significant in monitoring
the progression of viral infection and efficiency of the applied
treatment. One such instance is in the treatment of HIV: more
than 33million people worldwide are living with HIV, and a large
number of them are in developing countries and resource-limited
areas.9 First-line antiretroviral treatment is becoming widely
available, and it greatly increases both the duration and quality of
life of HIV patients. However, this first-line treatment begins to
fail as the virus mutates and develops drug resistance. In order to
stop the global spread of drug resistance and provide proper
treatment for patients, it is critical to evaluate the HIV viral load at
regular intervals (every 3 to 4 months) after the initial treatment is
shown to be effective. Moreover, HIV viral load measurement is a
particularly useful tool for diagnosing and evaluating the status of
HIV infection in children under age 18 months,10 as persisting
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ABSTRACT: In this paper, we are working toward a problem of
great importance to global health: determination of viral HIV
and hepatitis C (HCV) loads under point-of-care and resource
limited settings. While antiretroviral treatments are becoming
widely available, viral load must be evaluated at regular intervals
to prevent the spread of drug resistance and requires a quanti-
tative measurement of RNA concentration over a wide dynamic
range (from 50 up to 106 molecules/mL for HIV and up to 108
molecules/mL for HCV). “Digital” single molecule measure-
ments are attractive for quantification, but the dynamic range of
such systems is typically limited or requires excessive numbers of compartments. Here we designed and tested two microfluidic
rotational SlipChips to perform multivolume digital RT-PCR (MV digital RT-PCR) experiments with large and tunable dynamic
range. These designs were characterized using synthetic control RNA and validated with HIV viral RNA and HCV control viral
RNA. The first design contained 160 wells of each of four volumes (125 nL, 25 nL, 5 nL, and 1 nL) to achieve a dynamic range of
5.2  102 to 4.0  106 molecules/mL at 3-fold resolution. The second design tested the flexibility of this approach, and further
expanded it to allow for multiplexing while maintaining a large dynamic range by adding additional wells with volumes of 0.2 nL and
625 nL and dividing the SlipChip into five regions to analyze five samples each at a dynamic range of 1.8  103 to 1.2  107
molecules/mL at 3-fold resolution. No evidence of cross-contamination was observed. The multiplexed SlipChip can be used to
analyze a single sample at a dynamic range of 1.7 102 to 2.0 107 molecules/mL at 3-fold resolution with limit of detection of 40
molecules/mL. HIV viral RNA purified from clinical samples were tested on the SlipChip, and viral load results were self-consistent
and in good agreement with results determined using the Roche COBAS AmpliPrep/COBAS TaqMan HIV-1 Test. With further
validation, this SlipChip should become useful to precisely quantify viral HIV and HCV RNA for high-performance diagnostics in
resource-limited settings. These microfluidic designs should also be valuable for other diagnostic and research applications,
including detecting rare cells and rare mutations, prenatal diagnostics, monitoring residual disease, and quantifying copy number
variation and gene expression patterns. The theory for the design and analysis of multivolume digital PCR experiments is presented
in other work by Kreutz et al.
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maternal antibodies can cause false positive result in the HIV
antibody test.
The hepatitis C virus (HCV) infection is also a significant
global healthcare burden, as it has been identified as one of the
major causes of liver disease and is one of the most common
coinfections of HIV.11 Recent breakthroughs in HCV treat-
ments, such as the approval of HCV drugs from Merck and
Vertex by the US Food and Drug Administration (FDA),
generated excitement,12,13 but the HCV viral load may still need
to be carefully monitored to determine the effectiveness of the
treatment. The viral load for chronic HCV ranges from 50 000 to
5 million international units per mL (IU/mL),14 while for
patients responding to antiviral treatment it will be significantly
lower.15 A successful treatment should result in undetectable
levels of HCV viral RNA, requiring HCV viral load measure-
ments capable of a wide dynamic range.
Currently, real time quantitative RT-PCR is the gold standard
for monitoring viral load for HIV, HCV, and other viral infec-
tions. However, this test is cost-prohibitive under resource-
limited settings and usually requires multiple instruments, highly
skilled technicians, and isolated rooms to prevent contamination;
therefore, it is still not accessible to patients in resource-limited
settings. Moreover, the efficiency of RT-PCR, the quality of
sample and selection of targets, and the methods for interpreta-
tion of the data have brought up increasing concerns for the
accuracy of quantifying RNA using RT-PCR.16,17 While a dip-
stick device has been developed that provides semiquantitative
measurements of HIV viral load after amplification in resource-
limited settings,18 no quantitative test exists to resolve a 3-fold
(0.5 log10) change in HIV RNA viral load, which is considered to
be clinically significant.19,20 Digital PCR is a method that per-
forms quantitative analysis of nucleic acids by detecting single
molecule of DNA or RNA and can provide an absolute count of
the nucleic acid copy number with potentially higher accuracy
compared to real time PCR.21,22 Digital PCR has been previously
demonstrated on various platforms, including well plates,22
pneumatically controlled integrated microfluidic systems,23,24
microdroplets,2527 spinning disk,28 and Openarray.29 However,
most of these methods still rely on complex instruments and
chips to generate a large number of small-volume reaction
compartments which are required for digital PCR.
SlipChip is a microfluidic platform that can manipulate liquid
samples from picoliter-to-microliter scales by relative move-
ment of different plates without the need for complex control
systems.30 The SlipChip has been previously used for multi-
plex PCR,31 digital PCR,32 and digital isothermal amplifica-
tion (RPA).33 Instead of using wells of uniform size, using
wells of multiple volumes to achieve the same dynamic range
can significantly reduce the total number of wells and increase
the spacing among wells to simplify imaging and downstream
analysis. The mathematical approach for experimental design
and statistical analysis for multivolume digital PCR (MV
digital PCR) has been characterized using DNA in an accom-
panying study.34
Here, we describe a SlipChip platform for quantitative analysis
of RNA with large dynamic range by MV digital RT-PCR. As
RNA is more susceptible to degradation under the testing
environment and requires a reverse transcription step for down-
stream PCR amplification, it was not obvious whether the
multivolume digital approach would apply to RT-PCR analysis
of RNA, and therefore we first characterized this SlipChip with a
serial dilution of a synthetic control RNA molecule of 906
nucleotides (906 nt). We also describe a second design of the
platform that can maintain a large dynamic range for five samples
simultaneously, allowing for multiplexed experiments. We vali-
dated this multiplexed system by using HCV control viral RNA
and HIV viral RNA together with internal controls. We also
showed the potential to use multivolume designs to quantify HIV
viral load at a large dynamic range by quantifying purified HIV
viral RNA from clinical patients’ samples.
’RESULTS AND DISCUSSION
We first characterized the performance of digital RT-PCR in a
multivolume digital SlipChip (design 1, Table 1) with a large
dynamic range that is required for viral load testing. This
SlipChip contained four different volumes (1 nL, 5 nL, 25 nL,
125 nL) with 160 wells each (Figure 1A) for a theoretical
dynamic range (lower dynamic range, LDR, to upper limit of
quantification, ULQ) of 5.2 102 to 4.0 106 molecules/mL at
3-fold resolution and a lower detection limit (LDL) of 1.2 102
molecules/mL in the final RT-PCR mixture. The LDR corre-
sponds to the lowest concentration that can be resolved from a 3-
or 5-fold higher concentration; the ULQ is the concentration
that has a 95% chance of generating at least one negative well and
is equal to the concentration calculated from three negative wells;
the LDL is the concentration that has a 95% chance of generating
at least one positive well and is equal to the concentration
calculated from three positive wells.34 Continuous fluidic paths
are generated by partially overlapping the wells in the top plate
and the wells in the bottom plate (Figure 1B,E). The design of
this SlipChip follows the general principles of dead-end filling35
for complete filling of aqueous reagents (Figure 1C,F). After
complete loading, the top plate is slipped (rotated) clockwise by
∼8 to break the fluidic path and overlay the wells filled with
solution with the wells in the facing plate used to control thermal
expansion31 (Figure 1D,G). The SlipChip is then placed on a flat
in situ adaptor for thermal cycling.
The theory for design and analysis of this multivolume
SlipChip are described in detail and validated by using digital
PCR for DNA in an accompanying study.34 In brief, concentra-
tions were calculated based on Most Probable Number (MPN)
theory3639 by combining the results from each volume (i = 1, 2,
3, 4) in eq 1 and solving for λ (concentration, molecules/mL),
where ni is the total number of wells at each volume, bi is the
number of negative wells at that volume, and vi is the well volume
(mL). Combining results allows formore precise identification of
the “most probable” concentration and also improves the con-
fidence interval. To find the confidence interval, the standard
deviation, σ, for ln (λ) is determined using eq 2, which was
derived based on the Fisher information.34,39
∑
m
i¼ 1
nivi ¼ ∑
m
i¼ 1
ðni  biÞvi
ð1 eviλÞ ð1Þ
σ ¼ 1ffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffi
λ2∑
vi2ni
eviλ  1
r ð2Þ
To validate the performance of themultivolume SlipChip with
RNA, we performed digital RT-PCR using a six order-of-
magnitude serial dilution of synthetic control RNA template
(906 nt). This control RNAwas synthesized from a control plasmid
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and purified by using a commercial purification kit (see Experi-
mental Section in Supporting Information). The concentration of
the stock solution of control RNA was measured spectrophotome-
trically by NanoDrop to be∼1.8 ng/μL, corresponding to∼4.1
1012 molecules/mL, which is not perfectly accurate and contains
background noise. Using the SlipChip and through statistical
analysis34 of all MV digital RT-PCR results (Figure 3), we obtained
a nominal real concentration of the control RNA in solution,
2.2  1012 molecules/mL and used this value as the true
concentration of all MV digital RT-PCR results reported in
Figure 3. A RT-PCR master mix containing EvaGreen Super-
Mix, RT-transcriptase, bovine serum albumin (BSA), and
primers was mixed with the RNA template solution. EvaGreen,
an intercalating dye, was used for end-point fluorescent imaging
after thermal cycling (Figure 2).
No false positives were observed after amplification in four
negative control experiments, as there was no significant increase
of fluorescent intensity in wells (Figure 2A). As the concentra-
tion of RNA template increased (the dilution factor decreased),
the fraction of positive wells in each set of individual volumes
was counted and the concentration of template in the RT-PCR
mix was calculated as described above (Figure 2BF). The
glass SlipChip was reused after being thoroughly cleaned with
piranha acid (3:1 sulfuric acid:hydrogen peroxide), plasma
cleaned, and resilanized with dichlorodimethylsilane (see Ex-
perimental Section in Supporting Information). Four to five
experiments were performed for each concentration of tem-
plate, and the calculated concentration of template RNA
showed good agreement within the expected statistical distri-
bution at each concentration and scaled linearly with the
expected concentration (Figure 3A). The results at the con-
centrations of 2.2 106, 2.2 105, 2.2 104, 2.2 103, 2.2
102, and 7.3 101molecules/mL in the RT-PCRmix were used
to estimate an initial stock concentration of control RNA of
approximately 2.2  1012 molecules/mL. The experimental
results across the concentrations agree well with the theoreti-
cally predicted34 distribution (Figure 3A,B). Of the 26 experi-
ments, 19 fall within the 95% confidence interval and 22 fall
Table 1. Summary of Detection Limit and Dynamic Range for Multivolume SlipChip in the RT-PCR Mix
number of wells molecules/mL
625 nL 125 nL 25 nL 5 nL 1 nL 0.2 nL LDLa LDR-5b LDR-3c ULQ-3d total volume per sample, μL
design 1 0 160 160 160 160 0 1.2  102 2.0  102 5.2  102 4.0  106 25
design 2A 16 32 32 32 32 32 2.0  102 4.0  102 1.8  103 1.2  107 15
design 2B 80 160 160 160 160 160 40 67 1.7  102 2.0  107 75
a Lower detection limit, the concentration that has a 95% chance of generating at least one positive well, corresponds to concentration calculated from
three positive wells. b Lower dynamic range, 5-fold resolution, lowest concentration that can be resolved from a 5-fold higher concentration. cLower
dynamic range, 3-fold resolution, lowest concentration that can be resolved from a 3-fold higher concentration. dUpper limit of quantification, 3-fold
resolution, the concentration that has a 95% chance of generating at least one negative well, corresponds to the concentration calculated from three
negative wells. See Kreutz et al.34 for further details of the theory.
Figure 1. Rotational multivolume SlipChip (well volumes: 1 nL, 5 nL,
25 nL, 125 nL). (A) Bright field image of the rotational SlipChip after
slipping to form isolated compartments, shown next to a U.S. quarter.
(BD) Schematics and (EG) bright field microphotograph show (B,
E) the assembled rotational SlipChip. (C, F) The SlipChip filled with
food dye after dead-end filling. (D, G) The SlipChip after rotational
slipping: 640 aqueous droplets of four different volumes (160 wells with
volumes of 1 nL, 5 nL, 25 nL, 125 nL each) were formed simultaneously.
In the schematics, blue dotted lines indicate features in the top plate, and
black solid lines represent the features in the bottom plate.
Figure 2. End-point fluorescence images of multivolume digital RT-
PCR performed on a rotational SlipChip for synthetic RNA template at
five different concentrations. (A) Control, containing no RNA template.
(BF) Serial dilution of 906 nt RNA template from 2.2 102 to 2.2
106 molecules/mL in the RT-PCR mix.
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within the 99% confidence interval. The confidence interval is
based only on the theoretical distribution, so it is reasonable
that the experimental distribution is a little broader due to
experimental variations such as dilution errors and RNA
degradation.
Over the dynamic range of the device, the contribution of
wells with different volumes to the calculated concentration
varies and is approximated in Figure 4A. As the concentration
of control RNA template increases (the dilution decreases), the
major contribution to the calculated final concentration shifts
from wells of large volume (125 nL) to wells of medium volume
(25 nL and 5 nL) and then to wells of small volume (1 nL). The
percent that the result from each volume contributes to σ (eq 2)
serves as an estimate of the relative contribution of that volume to
the concentration determined by all volumes on the entire chip.
The concentration calculated from analysis of positive and negative
wells of each of the volumes on the individual SlipChip was self-
consistent and was consistent with the calculated concentration
determined by combining all wells with different volumes
(Figure 4B). This result indicates thatmultivolumedigital approach
is fully compatible with analysis of RNA by RT-PCR.
To test whether multiplexing can be easily incorporated into
the SlipChip whilemaintaining the high dynamic range, wemodified
the design of the multivolume SlipChip by adding two additional
volumes (Table 1, design 2A): 0.2 nL (160 wells) and 625 nL (80
wells). When the rotational chip is split into five sections to
quantify five different analytes, the 0.2 nL wells extend the upper
limit of quantification with 3-fold resolution to 1.2  107
molecules/mL in the RT-PCR mix, and the 625 nL wells
maintain a reasonable lower detection limit of 2.0  102
molecules/mL and lower dynamic range with 3-fold resolution
at 1.8 103molecules/mL in the RT-PCRmix (Figure 5A). The
higher upper limit of quantification is required to quantify HCV
viral RNA, and the lower dynamic range and lower detection
limit are required for the HIV viral load test. Five different
solutions can be introduced into the SlipChip simultaneously
(Figure 5A) for multiplexed analysis.
As HCV is one of the most common coinfections for HIV
patients, we first validated this multiplex SlipChip with five-plex
panel: measurement of HIV viral RNA, measurement of HCV
control viral RNA, a negative control for HIV, a negative control
for HCV, and measurement of 906 nt control RNA in HCV
sample for quantification of sample recovery rate (Figure 5B,C).
The 906 nt control RNAwas the same one characterized by using
digital RT-PCR on the SlipChip (design 1; see Figure 1). HIV
viral RNA was purified from an archived sample of plasma
containing HIV (viral RNA estimated to be ∼1.5  106
molecules/mL) from a deidentified patient sample, and HCV
control viral RNA was purified from a commercial sample
containing control HCV virus (25 million IU/mL, OptiQuant-S
Figure 3. Performance of digital RT-PCR with synthetic RNA template
on the multivolume SlipChip over a 4 log10 dynamic range, comparing
the expected concentration of RNA in RT-PCRmix to (A) the observed
concentration, and (B) the ratio of the observed/expected concentra-
tion. Individual experimental results (green crosses) and average results
(red crosses) for concentration were plotted against the dilution level of
the RNA stock solution. Four to five experiments were performed at
each concentration, and some experimental results are overlapping. The
experimental results show a linear relationship with the dilution level and
fit within the expected distribution. The experimental results were used
to estimate an initial stock concentration, whose distribution was then fit
to the dilution level to provide the expected value (black curve) and 95%
confidence interval (gray curves).
Figure 4. (A) For each dilution, the approximate contributions of the
results from each well volume toward calculating the final concentration
were calculated based on the contributions of each volume to the
standard deviation, σ (eq 2). (B) Concentration of RNA template
calculated from the overall chip (combining all well volumes, solid bars)
and individual volumes (patterned bars) is self-consistent on the MV
digital RT-PCR SlipChip. Four experiments were performed with 2.2 
104molecules/mLof control RNA template (906 nt) in the RT-PCRmix.
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HCV Quantification Panel, Acrometrix) using the iPrep purifi-
cation instrument (see Experimental Section in Supporting
Information). As the final elution volume of purified nucleic acid
is generally smaller than the starting volume of plasma, there is a
concentrating effect on viral RNA after sample purification. To
characterize this concentrating effect, the 906 nt control RNA
with known concentration was added to the lysed plasma and was
quantified again after sample preparation. The ratio of the
concentration of 906 nt control RNA after/before sample
preparation is defined as the concentrating factor. The concen-
trating factors after sample purification were approximately 6.6
for HIV viral RNA and approximately 4.5 for HCV control viral
RNA. Primers for HIV and HCV were selected from previous
publications.40,41 Only one pair of primers was added to each
sample, and the experiment was repeated six times. In those six
experiments, no false positives were observed in either HIV or
HCV negative control panels after thermal cycling, and no cross-
contamination was observed among different panels. From these
six experiments, the average calculated concentration of HIV
viral RNA after purification was 7.9  106 molecules/mL with
standard deviation of 2.5 106 molecules/mL, corresponding to
1.2  106 molecules/mL with standard deviation of 3.7  105
molecules/mL in the original plasma sample. The average
concentration of HCV control viral RNA after purification was
1.0  108 molecules/mL with standard deviation of 4.4  107
molecules/mL, corresponding to 2.3  107 molecules/mL with
standard deviation of 9.7  106 molecules/mL in the original
control plasma sample. There is no universal conversion factor
from international units to copy number forHCV viral load; it is a
value dependent on the detection platform, including the proto-
cols and equipment used. Because the HCV concentration in the
original commercial sample was stated to be 2.5 107 IU/mL, the
conversion factor from international units to copy number for HCV
viral load in our test is approximately 0.9. The same conversion
number (0.9) was published for the Roche Amplicor HCVMonitor
v2.0 test when using a manual purification procedure.42
Table 1 summarizes the detection and quantification limits
and dynamic range for the two multivolume SlipChip designs
presented in this paper. Theory predicts that the dynamic range
of design 1 can be easily extended by adding a set of wells smaller
than 1 nL in volume and a set of wells larger than 125 nL in
volume.34 Therefore, if a larger dynamic range is required, the
multiplexed design (design 2A) can be used for a single sample
(design 2B). When using the entire chip for one sample, the 160
smallest wells (0.2 nL in volume) extend the upper limit of
quantification with 3-fold resolution to 2.0 107 molecules/mL
in the RT-PCR mix and the 80 largest wells (625 nL in volume)
extend the lower detection limit to 40 molecules/mL and lower
dynamic range with 3-fold resolution to 1.7 102molecules/mL
in the RT-PCR mix (Table 1, design 2B). This large dynamic
range would be useful for quantification of viral load. A RT-PCR
mix containing an HIV viral RNA sample (prepared as described
above and then serially diluted) with an expected concentration
of 51 molecules/mL was used to test the lower detection limit
of design 2B (see Experimental Section in Supporting In-
formation). We performed three negative control experiments
(without HIV viral RNA) in parallel, and no false positives were
observed. Six experiments were performed to quantify the viral
RNA concentration (see Figure S1 in the Supporting Informa-
tion for a representative experiment), and the average calculated
HIV viral RNA concentration in the RT-PCR mix was 70
molecules/mL with standard deviation of 20 molecules/mL,
corresponding to 32 molecules/mL with standard deviation of
9 molecules/mL in the original plasma sample.
To further validate the feasibility of using a rotational multi-
volume SlipChip to quantify HIV viral load, we used design 1 to
measure HIV viral RNA purified from two archived samples of
HIV-infected blood plasma from two different anonymous
Figure 5. A SlipChip for multiplexed, multivolume digital RT-PCR
with high dynamic range. (A) A photograph of a multiplex device for up
to five samples corresponding to designs 2A and 2B in Table 1 with a
total of 80 wells of 625 nL, 160 wells of 125 nL, 160 wells of 25 nL, 160
wells of 5 nL, 160 wells of 1 nL, and 160 wells of 0.2 nL. (B) Fluorescent
photograph of a multiplexed digital RT-PCR detection panel: (I)
measurement of internal control of 906 nt RNA template in HCV
sample; (II) HCV control viral RNA measurement; (III) negative
control for HIV (HIV primers with no loaded HIV RNA template);
(IV)HIV viral RNAmeasurement; (V) negative control for HCV (HCV
primers with no loaded HCV RNA template). Inset shows an amplified
area from HCV viral load test.
Figure 6. Multivolume digital RT-PCR for quantification of HIV viral
load in two patients’ samples. Input concentration was calculated from a
single clinical measurement for each patient using the RocheCAP/CTM
v2.0 system and was assumed to be the true concentration. Each
concentration was measured at least four times, and each individual
experiment is plotted as single point on the graph. The black solid line is
the predicted concentration based on the assumption that the clinical
measurement gave a true concentration. The gray solid lines were
calculated using MPN theory34 and represent the 95% confidence
interval for the predicted concentration.
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patients. The HIV viral RNA from each patient sample was
extracted and purified automatically using the iPrep purification
instrument (see Experimental Section in Supporting In-
formation), and concentrating factors of 7.1 and 6.6 were
achieved for the two different patient samples. Each patient
sample of purified HIV viral RNA was serially diluted and
characterized by MV digital RT-PCR on the SlipChip using
previously published primers,40 and each experiment was re-
peated at least four times (Figure 6). The same plasma samples
were characterized in a single experiment using the Roche
COBAS AmpliPrep/COBAS TaqMan HIV-1 Test, v2.0 (CAP/
CTM v2.0) according to the manufacturer’s recommendation,
and these values were treated as the standard for characterization.
The data from SlipChip were self-consistent for both patients
(Figure 6). Three negative control experiments using the same
primers but no HIV template did not show false positive, as no
increase of fluorescent intensity was observed (see Figure S2 in
Supporting Information). For patient 1, the results (Figure 6,
green crosses) were on average approximately 40% lower than
that predicted by the single-point measurement of the HIV viral
load using Roche CAP/CTM v2.0 (see Table S1 in Supporting
Information). There were important differences in the test de-
signs: while our experiment targets a single LTR region of HIV
RNA, the Roche CAP/CTM v2.0 test includes two HIV se-
quences: one in gag and another in LTR region;43 also, the two
tests use different detection methods (EvaGreen in our experi-
ment vs TaqMan probes in the Roche CAP/CTM v2.0 test) and
different internal controls. Therefore, additional experiments with
a large variety of patient samples from different virus subtypes are
needed to further optimize and validate the multivolume ap-
proach to measuring viral load. For patient 2, excellent agreement
with the Roche clinical measurementwas observed over the entire
range (Figure 6, red pluses, see also Table S2 in Supporting
Information). This difference in agreement between the two
methods for the two samples is not surprising, given that each
patient has a unique HIV viral genome, and the primers, internal
controls, and detectionmethod used in onemethodmay be better
suited to detect one patient’s viral genome than another’s. Overall,
taking into consideration the concentrating effect during sample
preparation, the lowest concentration of serially diluted HIV viral
RNA detected on the SlipChip corresponded to 37 molecules/mL
in the patient plasma, and the highest concentration corresponded
to 1.7 million molecules/mL in the patient plasma.
’CONCLUSIONS
Motivated by the problem of quantifying viral load under
point-of-care and resource-limited settings, here we have suc-
cessfully tested the applicability of multivolume digital assays34 to
quantitative analysis of RNA over wide dynamic range via digital
RT-PCR on two rotational SlipChips (Table 1). The first chip
has a dynamic range (at 95% CI) of 5.2  102 to 4.0  106
molecules/mLwith 3-fold resolution and lower detection limit of
1.2  102 molecules/mL. It was characterized using synthetic
control RNA, demonstrating that MV digital RT-PCR performs
in agreement with theoretical predictions34 over the entire
dynamic range (Figure 3). Results fromwells of different volumes
were mutually consistent and enabled quantification over a wide
dynamic range using only 640 total wells (Figure 4). This chip was
also validated with viral RNA from two HIV patients (Figure 6),
demonstrating good agreement with single-point measurements
performed on a Roche CAP/CTMv2.0 clinical instrument. Using
this chip, we were able to detect positive wells corresponding to a
concentration of 81 molecules/mL HIV viral RNA purified from
patient plasma in the RT-PCRmix, which corresponds to around
37molecules/mL in the original plasma samples.While below the
detection limit at 95% confidence interval, this concentration
should give at least one positive well 86% of the time, so it is not
surprising that all four of our experiments had at least one positive
well at this concentration.
In the second chip, we tested the scalability and flexibility of
the multivolume approach by introducing both multiplexed and
higher-range quantification. We added additional wells with
volumes of 0.2 nL and 625 nL and divided the SlipChip into five
individual regions. We did not find evidence of cross-contamina-
tion among samples on this rotational design, in agreement with
previous results on a translational SlipChip.31 This multiplexed
SlipChip was designed to test five samples, each at a dynamic
range (3-fold resolution) from 1.8 103 to 1.2 107 molecules/
mL with a lower detection limit of 2.0  102 molecules/mL.
Multiplexing capability (Figure 5) enables a number of features
on the same chip, including (i) incorporating negative controls,
(ii) measuring levels of control RNA to quantify the quality of
sample preparation, (iii) monitoring coinfections, (iv) designing
customized arrays for multiple targets, i.e. for nucleic acid targets
that require measurements with different dynamic ranges and
resolution, using wells of different sizes with customized numbers
of wells at each size for each target, and (v) allowing for flexibility
depending on technical and economic constraints by using the
same device to perform either more analyses of lower quality, but
at proportionally lower cost, or a single analysis of high quality
including wider dynamic range and higher resolution. If this
multiplexed SlipChip is used for a single sample, the dynamic
range of the device with 3-fold resolution is designed to be 1.7
102 to 2.0 107 molecules/mL with a lower detection limit of 40
molecules/mL. Even with only a modest concentrating effect
during sample preparation, this device would enable detecting
targets at 1020 molecules/mL in the original sample.
The high sensitivity of the this MV digital RT-PCR platform
could be valuable for a number of applications beyond viral load,
including detecting rare cells and rare mutations, prenatal
diagnostics, and monitoring residual disease. Besides monitoring
the HIV viral load of patients on antiretroviral treatments, this
approach is also a promising method to screen newborns whose
mothers are carrying HIV, where maternal HIV antibodies would
potentially interfere with the antibody test. In addition, similar
molecular diagnostics methods may be used to measure proviral
DNA in infants. This approach can also be applied to investiga-
tion of copy number variation44,45 and gene expression,4648
both for research and diagnostic settings.
The rotational format of SlipChip is attractive for resource-
limited settings because the movement is easy to control even
manually; for a chip with a 2 in. (50 mm) diameter an 8 rotation
moves the outer edge of the chip by ∼3.5 mm, a distance not
difficult tomove by hand especiallywith internal stoppers and guides.
At the same time, it moves the wells which are 2.8 mm from the
center by 0.39 mm. This feature is ideal for multivolume formats
but also can be taken advantage of in single-volume formats.
SlipChip is also particularly attractive for multivolume formats
due to its lack of valves and ease of operation. A number of
additional developments will increase the usefulness this chip.
The trade-offs between resolution, dynamic range, and the extent
of multiplexing of the multivolume SlipChip are described by
theory34 and can be mitigated by using different materials and
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fabrication methods to increase the number of wells while
keeping the footprint of the overall device the same. These
improvements can come from deeper wells in two-layer devices
or by creating multilayer devices. The designs characterized
in this paper were fabricated in glass, and a functional SlipChip of
a different design made from plastic by hot embossing was
previously demonstrated.35 For applications to resource-limited
settings, devices made in inexpensive materials such as plastics
would be desired.49 These designs should be compatible with a
number of sample preparation protocols being developed,5052
either integrated on-chip or performed off-chip. Additionally, the
SlipChip would be compatible with other amplification chemis-
tries that are currently being developed, such as polymerization
and depolymerization methods,5355 toe-hold initiated hybridi-
zation-based amplification,5658 and other chemical amplifica-
tions including silver-based amplification.59,60 When combined
with isothermal amplification methods, such as recombinase
polymerase amplification (RPA),33,61 loop-mediated amplifica-
tion (LAMP),62 strand-displacement amplification (SDA),63
helicase-dependent amplification (HDA),64 and rolling circle
amplification (RCA),65 and visual readout methods, the MV
digital RT-PCR SlipChip would make quantitative molecular
diagnostics accessible in resource-limited settings.
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